IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma

Confirmed partial responses by RECIST observed in 4 of 8 (50% ORR) evaluable First-Line MUM patients and in 11 of 35 (31% ORR) evaluable Any-Line MUM patients...

Related Keywords

Canada ,Sydney ,New South Wales ,Australia ,Toronto ,Ontario ,Matt Maurer ,Yujiros Hata ,Marcus Butler ,Marlana Orloff ,Vincent Hospital Sydney ,Sidney Kimmel Cancer Center ,Tumor Immunotherapy Program ,Nasdaq ,Pfizer ,Biosciences Inc ,Ocular Melanoma Physician Task ,Jefferson Health ,Associate Professor ,Vice President ,Clinical Oncology ,Medical Affairs ,Data Update ,Crizotinib Combination ,Tumor Shrinkage ,Disease Control Rate ,Overall Response Rate ,Tumor Reduction ,Study Follow Up ,Progression Free Survival ,Adjuvant Uveal Melanoma ,Uptake Value ,Medical Oncologist ,Skin Oncology Site Lead ,Princess Margaret Cancer Centre ,Ocular Melanoma Physician Task Force ,Hospital Sydney Limited ,Investigator Sponsored Trial ,Chief Executive Officer ,Investor Relations ,